- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sera Prognostics Inc (SERA)
The Sera Prognostics share price today is 1.88, view NASDAQ SERA stock exchange data. Track the latest Sera Prognostics share price with real-time updates on SERA stock performance including market cap, day range, 52-week range and dividend yield. Access SERA charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.87
1.93
52 wk Range
1.37
4.09
SERA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.871.93
52 wk Range
1.374.09
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SERA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.00
Upside
+165.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 13G SERA PROGNOSTICS For: 1 May
- Investing.com
- Form 144 SERA PROGNOSTICS For: 21 April
- Investing.com
- Form 13G SERA PROGNOSTICS For: 1 May
- Investing.com
- Form 144 SERA PROGNOSTICS For: 21 April
- Investing.com
- Form 144 SERA PROGNOSTICS For: 24 March
- Investing.com
- Form 424B5 Sera Prognostics Inc For: 18 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.00
(+165.96% Upside)
Sera Prognostics Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue plunged 63.2% YoY to $14K vs. $96.7K forecast (85.5% miss); EPS of -$0.17 beat estimate of -$0.18; stock fell 3.72% to $1.86
- Net loss widened to $8.4M from $8.2M YoY; operating expenses rose to $9.4M; gross margin remained deeply negative at -102% over trailing 12 months
- Management expects modest, uneven 2026 revenue as reimbursement campaigns continue; anticipates stronger pull-through in late 2026 and into 2027
- Cost reduction initiatives targeting ~$10M in annualized savings, with majority of benefits expected in 2027; cash runway extended through 2029
- Strategic pivot from clinical-stage to targeted commercial initiatives; shares down 38.6% YTD, trading near 52-week low amid commercialization challenges
Last Updated: 07-05-2026, 04:40 am
Read Full TranscriptEarnings
Latest Release
06-05-2026
EPS / Forecast
-0.17 / -0.18
Revenue / Forecast
14K / 96.67K
Compare SERA to Peers and Sector
Metrics to compare | SERA | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipSERAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −2.0x | −0.5x | |
PEG Ratio | −0.07 | −0.05 | 0.00 | |
Price/Book | 1.0x | 1.1x | 2.6x | |
Price / LTM Sales | 908.9x | 23.3x | 3.2x | |
Upside (Analyst Target) | 176.2% | 92.3% | 47.8% | |
Fair Value Upside | Unlock | 8.7% | 5.9% | Unlock |
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Sera Prognostics (SERA) Share Price Today?
The Sera Prognostics share price today is 1.88.
What is the current Sera Prognostics (SERA) share price and day range?
As of 09-05-2026, the Sera Prognostics share price is 1.88, with a previous close of 1.92. The share price has ranged from 1.87 to 1.93 today, while the 52-week range spans from 1.37 to 4.09.
What Is the Sera Prognostics Market Cap?
As of today, Sera Prognostics market cap is 73.62M.
What Is the Sera Prognostics (SERA) Share Price Target?
The average 12-month share price target for Sera Prognostics is 5.00, with a high estimate of 5 and a low estimate of 5. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +165.96% Upside potential.
What Is Sera Prognostics's Earnings Per Share (TTM)?
The Sera Prognostics EPS (TTM) is -0.65.
When Is the Next Sera Prognostics Earnings Date?
Sera Prognostics will release its next earnings report on 12-08-2026.
From a Technical Analysis Perspective, Is SERA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Sera Prognostics Trade On?
Sera Prognostics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Sera Prognostics?
The stock symbol for Sera Prognostics is "SERA."
How Many Times Has Sera Prognostics Stock Split?
Sera Prognostics has split 0 times.
How Many Employees Does Sera Prognostics Have?
Sera Prognostics has 72 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.